

| | |
|-------------------------|------------------|
| Reference: | FOI.17124.25 |
| Subject: | Multiple Myeloma |
| Date of Request: | 17 April 2025 |

Requested:

1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.
2. Of the multiple myeloma patients treated over the past 6 months, how many were treated with the following:
 - Any other systemic anti-cancer therapy
 - Belantamab Mafodotin [Blenrep]
 - Belantamab Mafodotin [Blenrep] with bortezomib and dexamethasone
 - Belantamab Mafodotin [Blenrep] with pomalidomide and dexamethasone
 - Bortezomib [Velcade] monotherapy or with dexamethasone
 - Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)
 - Bortezomib, thalidomide and dexamethasone [VTD]
 - Carfilzomib [Kyprolis] and dexamethasone
 - Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone
 - Daratumumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone
 - Daratumumab [Darzalex] monotherapy
 - Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)
 - Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)
 - Elranatamab
 - Idecabtagene vicleucef [Abecma]
 - Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)
 - Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd)
 - Lenalidomide [Revlimid] and dexamethasone
 - Lenalidomide [Revlimid] monotherapy
 - Panobinostat in combination with Bortezomib and Dexamethasone
 - Pomalidomide [Imnovid] and dexamethasone
 - Selinexor and dexamethasone
 - Selinexor, Bortezomib [Velcade] and dexamethasone
 - Talquetamab
 - Teclistamab [Tecvayli]

Response:

1. Hywel Dda University Health Board (UHB) has treated one hundred and forty-eight (148) patients diagnosed with Multiple Myeloma, during the period 1 October 2024 and 31 March 2025.
2. The UHB provides, within the table below, the number of patients diagnosed with Multiple Myeloma that were treated with each of the named treatments, during the period 1 October 2024 and 31 March 2025.

| Treatments | Patients |
|---|-----------------|
| Any other systemic anti-cancer therapy | * |
| Belantamab Mafodotin [Blenrep] | * |
| Belantamab Mafodotin [Blenrep] with bortezomib and dexamethasone | 0 |
| Belantamab Mafodotin [Blenrep] with pomalidomide and dexamethasone | 0 |
| Bortezomib [Velcade] monotherapy or with dexamethasone | * |
| Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd) | * |
| Bortezomib, thalidomide and dexamethasone [VTD] | 0 |
| Carfilzomib [Kyprolis] and dexamethasone | 0 |
| Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone | 7 |
| Daratamumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone | 15 |
| Daratumumab [Darzalex] monotherapy | 27 |
| Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd) | 5 |
| Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd) | 16 |
| Elranatamab | 0 |
| Idecabtagene vicleucel [Abecma] | 0 |
| Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) | 10 |
| Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd) | 5 |
| Lenalidomide [Revlimid] and dexamethasone | 27 |
| Lenalidomide [Revlimid] monotherapy | 24 |
| Panobinostat in combination with Bortezomib and Dezamethasone | 0 |
| Pomalidomide [Imnovid] and dexamethasone | * |
| Selinexor and dexamethasone | 0 |
| Selinexor, Bortexomiv [Velcade] and dexamethasone | 0 |
| Talquetamab | 0 |
| Teclistamab [Tecvayli] | 0 |
| Total | 148 |

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.